The analyses of the Nanostring cohort demonstrated that the mRNA expression of FAP could be a predictive biomarker for immunotherapeutic benefits, and after immune checkpoint therapy for GC, there were possible beneficial effects for patients with lower FAP mRNA levels. Here, FAP is linked to gastric cancer.